University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital
Search Site | Find a Doctor
Print this page
FONT SIZE
Home > Doctors > Flavio G. Vincenti

Flavio G. Vincenti, M.D.

Kidney and pancreas specialist

Dr. Flavio Vincenti, a kidney and pancreas transplant specialist, is board certified in internal medicine and nephrology. He came to UCSF Medical Center in 1975 for a transplant nephrology fellowship and was appointed a member of the kidney transplant team.

His memberships in professional organizations include the American Society of Nephrology, American Society of Transplantation, International Society of Nephrology and Transplantation Society. He is a co-leader of the kidney section of the Immune Tolerance Network for kidney transplantation. In addition, he is on the editorial board of the American Journal of Kidney Diseases and Graft.

In 1978, Vincenti was one of the authors of an article in the New England Journal of Medicine about the role of blood transfusions in improving kidney transplants. He also wrote a series of articles on the complications of transplants and has been a leading investigator and author on the use of anti interleukin 2 receptor monoclonal antibodies. In addition, he is a proponent of minimizing immunosuppressive drugs after transplants.

Conditions & Treatments

Clinics

Connie Frank Transplant Center at UCSF
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Phone: (888) 894-6361
Pre-Kidney Fax: (415) 353-8708
Post-Kidney Fax: (415) 353-8381

Hours: 8 a.m. – 5 p.m.

Pancreas Transplant Services
400 Parnassus Ave., Seventh Floor
San Francisco, CA 94143
Phone: (415) 353-1551
Pre-Pancreas Transplant Fax: (415) 353-8708,
Post-Pancreas Transplant Fax: (415) 353-4183

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Flavio G. Vincenti

Additional Languages

Arabic
French
Italian

Education

American University Medical Center of Beirut 1971

Residencies

American University Medical Center of Beirut, Internal Medicine 0

Fellowships

Emory University Hospital, Nephrology 1975

Selected Research and Publications

  1. Vincenti F. Beyond belatacept: praise and progress for the FDA. Am J Transplant. 2012 Mar; 12(3):513-4.
  2. Wojciechowski D, Vincenti F. Targeting JAK3 in kidney transplantation: current status and future options. Curr Opin Organ Transplant. 2011 Dec; 16(6):614-9.
  3. Jen KY, Nguyen TB, Vincenti FG, Laszik ZG. C4d/CD34 double-immunofluorescence staining of renal allograft biopsies for assessing peritubular capillary C4d positivity. Mod Pathol. 2012 Mar; 25(3):434-8.
  4. Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J, Lang P, Urrea EM, Massari P, Mondragon-Ramirez G, Reyes-Acevedo R, Rice K, Rostaing L, Steinberg S, Xing J, Agarwal M, Harler MB, Charpentier B. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant. 2012 Jan; 12(1):210-7.
  5. Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F. Belatacept-versus Cyclosporine-Based Immunosuppression in Renal Transplant Recipients with Pre-existing Diabetes. Clin J Am Soc Nephrol. 2011 Nov; 6(11):2696-704.
  6. Vincenti F, Dritselis A, Kirkpatrick P. Belatacept. Nat Rev Drug Discov. 2011 Sep; 10(9):655-6.
  7. Wojciechowski D, Vincenti F. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation. Semin Immunol. 2011 Jun; 23(3):157-64.
  8. Webber A, Hirose R, Vincenti F. Novel strategies in immunosuppression: issues in perspective. Transplantation. 2011 May 27; 91(10):1057-64.
  9. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, Vincenti F. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011 May 15; 91(9):976-83.
  10. Friman S, Arns W, Nashan B, Vincenti F, Banas B, Budde K, Cibrik D, Chan L, Klempnauer J, Mulgaonkar S, Nicholson M, Wahlberg J, Wissing KM, Abrams K, Witte S, Woodle ES. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant. 2011 Jul; 11(7):1444-55.
  11. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase 1, single-dose study of fresolimumab, an anti-TGF-ß antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011 Jun; 79(11):1236-43.
  12. Humar A. Response to questions regarding the design and results of the IMPACT trial. Am J Transplant. 2011 Jan; 11(1):177-8.
  13. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation. 2010 Dec 27; 90(12):1427-31.
  14. Posselt AM, Szot GL, Frassetto LA, Masharani U, Tavakol M, Amin R, McElroy J, Ramos MD, Kerlan RK, Fong L, Vincenti F, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation. 2010 Dec 27; 90(12):1595-601.
  15. Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010 Dec 27; 90(12):1528-35.
  16. Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation. 2010 Dec 27; 90(12):1521-7.
  17. Ferguson R, Grinyó J, Vincenti F, Kaufman DB, Woodle ES, Marder BA, Citterio F, Marks WH, Agarwal M, Wu D, Dong Y, Garg P. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant. 2011 Jan; 11(1):66-76.
  18. Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol. 2011 Feb; 6(2):430-9.
  19. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010 Dec; 56(6):1127-39.
  20. Posselt AM, Bellin MD, Tavakol M, Szot GL, Frassetto LA, Masharani U, Kerlan RK, Fong L, Vincenti FG, Hering BJ, Bluestone JA, Stock PG. Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab. Am J Transplant. 2010 Aug; 10(8):1870-80.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions by logging on to UCSF Profiles.

Home • Terms of Use • Site Map • Contact Us       © 2002 - 2012 The Regents of The University of California